#Ghent #Belgium #XEOS #BrIMA Study #AURA 10

Introduction

In a groundbreaking development for breast cancer surgery, XEOS, a forward-thinking medical technology company, has published significant findings from its BrIMA (Breast cancer Intraoperative Margin Assessment) study in the prestigious journal JAMA Surgery. The study highlights the effectiveness of the advanced AURA 10® PET-CT system in improving intraoperative margin assessments, a pivotal aspect of successful breast-conserving surgeries.

Significance of the Study

Breast-conserving surgery, while a preferred option for many women diagnosed with early-stage breast cancer, often faces a considerable challenge: the issue of positive margins. Research indicates that positive margins affect approximately 12% to 30% of patients, often leading to the necessity of additional surgeries which can incur further emotional and physical distress for the patients as well as increased healthcare costs.

Key Findings of the BrIMA Study

The BrIMA study, which represents the largest multicenter evaluation of specimen PET-CT regarding intraoperative margin assessment in breast surgery to date, reveals that surgeons utilizing the AURA 10® system achieved markedly improved success rates in identifying and managing positive margins.

1. Increased Success Rates: For patients with invasive ductal carcinoma (IDC), the most prevalent form of breast cancer, the intraoperative success rate jumped from 83.3% to an impressive 95.2% when employing the PET-CT imaging.

2. Broader Impact: When considering all breast cancer types included in the research, the overall success rate shifted from 76.4% without intraoperative margin assessment to 91.9% with the implementation of PET-CT.

3. Safety and Agreement: The BrIMA findings are underscored by the absence of any device-related adverse events, and a strong concordance among surgeons regarding the interpretation of PET-CT images.

Vincent Keereman, the Founder and CEO of XEOS, emphasized the high relevance of this technology during surgical procedures: "The key takeaway from the BrIMA study is that surgeons are equipped with critical insights at the precise moment they need to make decisions. This real-time feedback can significantly change the trajectory of patient care and outcomes."

Advancements in Imaging Technology

The AURA 10® PET-CT system stands out from traditional methods by delivering comprehensive three-dimensional imaging of the entire excised specimen, rather than merely assessing parts of it. This novel system, designed for integration within the surgical workflow, provides results in approximately ten minutes, enabling immediate decision-making while the patient remains on the operating table.

Dr. Menekse Göker, the primary author of the publication and a breast surgeon at Ghent University Hospital, commented on the importance of these results, affirming that the AURA 10® system plays a transformative role in routine surgical practice by offering reliable intraoperative visualization across various breast cancer subtypes.

Future Implications

As healthcare systems increasingly prioritize enhancing surgical outcomes and minimizing reoperations, the implications of the BrIMA study are vast. The findings suggest that specimen PET-CT could facilitate better intraoperative decision-making, ultimately aiming to improve overall patient care and satisfaction in surgical oncology settings.

Moreover, these insights may pave the way for potential applications beyond breast cancer treatments, offering a foundational step towards the integration of advanced imaging technologies in various oncologic procedures.

Conclusion

In summary, the BrIMA study signifies a substantial evolution in breast cancer surgery, presenting a new horizon in how surgeons can utilize advanced imaging techniques to improve patient outcomes. With the promise of reducing reoperations and addressing positive margins during surgery, XEOS's AURA 10® has the potential to redefine best practices in surgical oncology. For more in-depth findings, the complete publication is available in JAMA Surgery.